Treatment of metastatic nonseminomatous germ cell tumors of the testis: Significance of the International Consensus Prognostic Classification as a prognostic factor-based staging system

International Journal of Urology

Volumn 5, Issue 6, 1998, Pages 562-567

  Shinohara, Nobuo ^a   Hioka, Takaya ^a   Harabayashi, Toru ^a   Demura, Takayoshi ^a   Kashiwagi, Akira ^b   Nagamori, Satoshi ^b   Koyanagi, Tomohiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

Author keywords

Induction chemotherapy; Metastatic nonseminomatous germ cell tumors; Prognosis; Risk criteria

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FOLLOW UP; GERM CELL TUMOR; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; TESTIS NONSEMINOMA CANCER;

EID: 0032444686     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00413.x     Document Type: Article

References (16)

1. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-1440.
2. Birch R, Williams SD, Cone A, Einhorn LH, Roark P, Tuner S, Greco FA. Prognostic factors for favorable outcome in disseminated germ cell rumors. J Clin Oncol 1986; 4:400-407.
3. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore WF Jr, Vugrin D, Scher H, Nisselbaum J, Golbey RB. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43:3403-3407.
4. Asao N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, Ahlstrom S, Fossa SD. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818-826.
5. The International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
6. Bosl GJ, Yagoda A, Whitmore WF Jr, Sogani P, Herr H, Vugrin D, Dukeman M, Golbey R. VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors. Am J Clin Oncol 1984;7:327-330.
7. Bosl GJ, Gluckman R, Geller NL, Golbey Rb, Whitmore WF Jr, Herr H, Sogani P, Morse M, Martin N, Bains M. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 1986;4:1493-1499.
8. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy vs. a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ cell tumors. J Clin Oncol 1988;6:1031-1040.
9. The Japanese Urological Association and The Japanese Pathological Society. General rules for clinical and pathological studies on testicular tumors. 1st ed. Tokyo: Kanehara, 1984.
10. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-546.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-1781.
13. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ. Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol 1988;6:786-792.
14. Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85:1828-1835.
15. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzer B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumors. Eur J Cancer 1993; 29A:2225-2231.
16. Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997;15:2553-2558.